Navigation Links
Neogen reports 27% increase in quarterly net income
Date:3/26/2013

operating officer. "We are also pleased to report third quarter sales that were not only substantially above last year, but also higher than our traditionally strong second quarter. Growth in revenues from new products launched in the last 18 months along with solid growth in many of our existing market segments contributed to the strong third quarter sales performance."

The third quarter was the 84th quarter of the past 89 quarters that Neogen reported revenue increases as compared with the previous year — including all consecutive quarters in the last eight years.

"As our balance sheet shows, we have been able to continue to grow our available cash balance even with three cash acquisitions within the past 12 months," said Steve Quinlan, Neogen's chief financial officer. "This positions us well to pursue all available avenues of growth, including further synergistic acquisitions."

Sales of Neogen's extensive line of food allergen tests increased in the third quarter of FY 2013 when compared to the prior year's third quarter, as food processors continued implementing programs to comply with components of the United States' Food Safety Modernization Act (FSMA) of 2011. The allergen testing by food processors helps prevent the contamination of non-allergenic products with known food allergens.

Sales of Neogen's test kits for meat speciation, and complementary Scotland-based laboratory services, more than tripled on a quarter-to-quarter comparison as the company responded to the horse meat scandal in Europe, where product represented as ground beef was found to contain horse and pig meat. This response helped the company's Neogen Europe subsidiary achieve an 18% increase in revenues for the third quarter when compared to the prior year quarter.

The third quarter also saw a significant increase in the sales of Neogen's line of dairy antibiotic tests. This increase, when compared to FY 2012's third quarter, was due to timing of
'/>"/>

SOURCE Neogen Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Neogen Corporation Announces 2nd Quarter Results Conference Call
2. Neogen Reports Second Quarter Results
3. Neogen Launches Fully Quantitative Lateral Flow Test for DON
4. Neogen launches the fastest molecular pathogen test
5. Neogen acquires Igenity from Merial
6. Neogen Corporation Announces Year-End Results Conference Call
7. Neogen reports year end results
8. Neogen Corporation Announces 1st Quarter Results Conference Call
9. Neogen reports 30% increase in quarterly net income
10. Neogen Corporation Announces 3rd Quarter Results Conference Call
11. Neogen launches rapid tests for ractopamine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , ... July 30, 2015 , ... ... of a field clinical study of its canine osteoarthritis stem cell product, currently ... Therapeutics (Kansas City, KS) and will be marketed in the US by Aratana. ...
(Date:7/30/2015)... Ascendis Pharma A/S (Nasdaq: ASND ... TransCon technology to address significant unmet medical needs, ... Phase 2 study to evaluate the safety and ... treatment-naïve, pre-pubertal children with growth hormone deficiency, or ... the top-line results from our Phase 2 pediatric ...
(Date:7/30/2015)... ... July 30, 2015 , ... GEA's ... designed for continuous operation up to 1500 bar. The sanitary design gauge of ... preventing toxic contamination. , The Pony™ NS2006L homogenizer is an ideal solution for ...
(Date:7/29/2015)... -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; ... to progressing its ground-breaking technology platforms to Phase 1 ... the Company delivers the best value for shareholders. ... said the Company currently had an extensive program of ... and academic partnerships and initiatives, and he was working ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... 5 BioSpecifics,Technologies Corp. (OTC Bulletin Board: BSTC), ... products, announced today that,it has signed an agreement ... future royalty obligations for Peyronie,s disease by buying ... payment., BioSpecifics has modified its previously announced ...
... to Expand Business Development Efforts, SALT LAKE ... company,focused on the development of molecular diagnostic and ... today that Joe Ross has,joined the executive management ... Initiatives., In this new role, Ross will ...
... BFRM ) today announced its financial results for the ... sales were $16.7,million for the quarter ended June 30, 2008 ... 2007, an increase of $1.3 million or 8.4%.,The net loss ... as,compared to a net loss of $4.9 million for the ...
Cached Biology Technology:BioSpecifics Technologies Corp. Buys Down Royalties for Peyronie's Disease 2Axial Biotech appoints new Vice President of Strategic Initiatives 2BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 2BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 3BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 4BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 5BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 6BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 7BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 8BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 9
(Date:6/24/2015)... This report provides market analysis of the ... It contains an analysis of the drivers, challenges, and ... from the short, medium, and long term perspective landscapes. ... and technology trends that currently, prevail in the market. ... to efficiently manage the increasing marine traffic and increasing ...
(Date:6/24/2015)... 22, 2015 Research ... of the "Huawei Ascend Mate 7 Fingerprint ... their offering. Huawei,s technological choice for ... direction than Apple,s and Samsung,s one. The Ascend ... by Fingerprint Cards, a main actor in capacitive ...
(Date:6/23/2015)... 2015   MedNet Solutions , an innovative ... spectrum of clinical research, is pleased to announce ... the company,s intuitive, flexible and affordable cloud-based eClinical ... Stevie® Award by the American Business Awards ... category.  The American Business Awards are considered the ...
Breaking Biology News(10 mins):Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2
... Elsevier, a world-leading provider of scientific, technical ... leading German scientist, Professor Dr. Manfred T. Reetz ... Meerwein Research Professor at Philipps-Universitt, Marburg, has been ... Creativity in Organic Chemistry. The Executive ...
... demonstrated how a species of flatworm overcomes the ageing ... in the Proceedings of the National Academy of ... the Biotechnology and Biological Sciences Research Council (BBSRC) and ... the possibilities of alleviating ageing and age-related characteristics in ...
... A striking discovery in the study of human genetics ... on EurekAlert! in 2011. Researchers found that part of ... that they interbred with early human populations. Breakthroughs ... in zoology, psychology, and astrobiology, were also featured in ...
Cached Biology News:Leading German Researcher awarded Elsevier's 2011 Tetrahedron Prize 2Immortal worms defy aging 2Immortal worms defy aging 3Story on human genetic origins is one of EurekAlert!’s most-visited releases in 2011 2Story on human genetic origins is one of EurekAlert!’s most-visited releases in 2011 3Story on human genetic origins is one of EurekAlert!’s most-visited releases in 2011 4
ANTI S. GROUP AG:H...
This kit only detects beta-galactosidase activity at pH 6 in cultured cells andtissue sections. Beta-galactosidase activity at pH 6 ispresent only in senescent cells, and is not found inpresenescent...
2,4,6, Trinitrophenyl hapten is conjugated to lipopolysaccharide (LPS)....
... need to make your strain of cells competent ... for preparing competent cells are comprehensive and customized ... service offers: High transformation efficiencies ... Quality control performance testing Great ...
Biology Products: